# Pulmonology (asthma) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN-TD
- Date: 1948-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Samuel Oyelowo-Brandt, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Viola Harrington-Mbeki, MD

## Reason for consultation

Four months of wheeze, night cough and breathlessness on stairs in a 72-year-old never-smoking woman who has been told for many years that she has asthma but has never had lung function testing and has been treated with albuterol alone. Please confirm or refute asthma with spirometry before and after bronchodilator, DLCO and FeNO, help separate it from COPD and heart disease, and advise on treatment. **S**

## History

Mrs. Bethune, 72, is seen at the request of Dr. Harrington-Mbeki for four months of worsening wheeze, night cough and breathlessness on exertion, on a background of asthma diagnosed clinically many years ago and never confirmed. She uses albuterol most days and has never had an inhaled corticosteroid. Triggers are colds, dust, perfume and humid air. She has never smoked. She has nasal blockage, postnasal drip and reduced smell, and evening heartburn. She has had no oral corticosteroid course, emergency visit or admission for asthma in the past year. **S**

## Examination

| System | Finding |
|---|---|
| General | Composed, speaking in full sentences; blood pressure 146/86, pulse 78; oxygen saturation 96 percent |
| Nose | Swollen, pale inferior turbinates; no polyps visible by anterior rhinoscopy |
| Respiratory | Scattered expiratory wheeze on forced expiration; no crackles |
| Cardiovascular | Regular rhythm; no gallop; jugular venous pressure not raised; no edema |

BP 146/86 mmHg; pulse 78 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 87.6 kg; BMI 33 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Harrington-Mbeki's intake note and results: chest X-ray with mild hyperinflation and normal heart size; ECG with LVH by voltage; blood eosinophils 0.42; BNP 48; Asthma Control Test 13. This morning, in our laboratory, with GLI Global race-neutral equations: FEV1 1.30 L (64 percent predicted) before and 1.57 L after albuterol 400 mcg (+270 mL, +21 percent); FEV1/FVC 0.64 before and 0.72 after; DLCO 17.2 (92 percent predicted); FeNO 46 ppb. Total IgE 210 IU/mL; specific IgE positive to house dust mite, negative to cat, dog, cockroach and mold. Transthoracic echocardiogram this morning: ejection fraction 62 percent, mild concentric LVH, grade 1 diastolic dysfunction, normal left atrium and right ventricle, estimated pulmonary artery systolic pressure 28 mmHg. FEV1 before bronchodilator: 1.3 L (low); FEV1 after bronchodilator: 1.57 L; FEV1 percent predicted before bronchodilator: 64% (low); FEV1/FVC before bronchodilator: 0.64 (low); FEV1/FVC after bronchodilator: 0.72; DLCO: 17.2 mL/min/mm[Hg]; FeNO: 46 [ppb] (high); Left ventricular ejection fraction: 62%; Total IgE: 210 [IU]/mL (high); Asthma Control Test: 14. All results are synthetic.

## Assessment

1. **Asthma, confirmed, uncontrolled, with type 2 inflammation** (J45.40). Question 1: this is asthma. The 270 mL, 21 percent bronchodilator response confirms variable airflow obstruction, and the post-bronchodilator FEV1/FVC of 0.72 with a normal DLCO argues against COPD, which in any case would be unusual in a never smoker. Question 2: read with race-neutral GLI Global equations, as the American Thoracic Society now recommends, her FEV1 is 64 percent of predicted; race-based equations would have set a lower predicted value for her and made the impairment look milder, which is one way asthma in Black patients has been under-recognized. Question 4: FeNO 46 ppb, eosinophils 0.42, total IgE 210 and dust mite sensitization show type 2 (allergic and eosinophilic) inflammation. She does not have severe asthma, because she has never been treated with an inhaled corticosteroid, so biologic therapy is not indicated now; if she remained uncontrolled on optimized step 4 to 5 treatment, or had repeated oral corticosteroid courses, she would qualify for assessment, and anti-IL-5 or anti-IL-4 receptor therapy would fit her phenotype. **S**
2. **Hypertensive heart disease without heart failure** (I11.9). Question 1, continued: her breathlessness is not cardiac. BNP is 48, the ejection fraction is normal, the left atrium is not enlarged and there is no pulmonary hypertension. The LVH and grade 1 diastolic dysfunction reflect untreated hypertension, which should be treated; a beta-blocker should be avoided. **S**
3. **Chronic nasal symptoms** (R09.81). Question 5: probable chronic rhinosinusitis, which worsens asthma control; nasal endoscopy will confirm it and look for polyps, which would also matter for any later biologic choice. Reflux should be treated for its own symptoms; obesity can add to breathlessness, but here asthma is the main cause. **S**

## Recommendations

1. Question 3: stop albuterol alone and start GINA track 1 budesonide-formoterol 160/4.5 mcg as maintenance and reliever: one inhalation twice daily and one as needed, up to 12 a day (step 3).
2. Check inhaler technique and adherence at every visit and correct them before any step-up; add a spacer if the technique with the pressurized inhaler is poor.
3. Question 6: a written asthma action plan with peak flow zones, a peak flow meter and a diary to set her personal best; review six weeks after starting and within a week of any exacerbation; Asthma Control Test at each visit; repeat spirometry and FeNO after three to six months.
4. Treat the upper airway: intranasal fluticasone and saline now, and ear, nose and throat review with nasal endoscopy.
5. Treat symptomatic reflux with an eight-week course of a proton pump inhibitor and meal timing; it is not a treatment for asthma.
6. Hypertension: amlodipine or another agent without beta-blockade; avoid nonselective beta-blockers, including eye drops.
7. Biologic therapy is not indicated now; repeat blood eosinophils and reassess if asthma is uncontrolled on step 4 to 5 treatment or she needs two or more oral corticosteroid courses in a year.
8. Vaccines: pneumococcal vaccine now; influenza, COVID-19 and RSV in the autumn; house dust mite covers for the bedding.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Harrington-Mbeki the same day. The results were explained to Mrs. Bethune in plain words, including why the reference equations matter and why her breathlessness is asthma rather than her heart or her weight. She asked for a copy of her results and decides who else receives this note. **S**

## Follow-up

Pulmonology review after the repeat spirometry in three to six months, or sooner if an exacerbation occurs or control is not achieved; Dr. Harrington-Mbeki continues primary care and shares the monitoring. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2022;79(17):1757-1780 (PMID 35379504) (2022), American Heart Association, American College of Cardiology and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Pate CA, et al. Asthma Surveillance - United States, 2006-2018. MMWR Surveill Summ 2021;70(5):1-32 (PMID 34529643) (2021), Centers for Disease Control and Prevention
